InvestorsHub Logo
Followers 193
Posts 703
Boards Moderated 0
Alias Born 10/27/2016

Re: None

Thursday, 03/08/2018 10:35:46 AM

Thursday, March 08, 2018 10:35:46 AM

Post# of 346
I've been a professional investor for 24 years. I expected it to perform well (that's why I have pretty decent exposure in INNT). But, the catalyst for the performance I'm still unsure about. A few ideas:

1. The company's technology has merit to strategics (e.g. other pharma companies). I haven't asked management if there are any current strategic discussions because, if there are, I don't want to know. One reason I still invest professionally after 24 years - I don't trade on inside information.

2. I also know some friends of mine that were trying to buy the stock in the $5 - $10 range. They told me it was really hard to do...not much stock around to buy. So, simply put, holders of the stock are pretty happy and want to see the Larazotide clinical trial play out.

3. Larazotide holds promise in nonalcoholic steatohepatitis (NASH). This is a large market indication with no good options presently. This would add significantly to the "fair" market value of the company.

Those are possible fundamental explanations...but it also may just be the 'shit happens'.